The goal of this clinical research study is to learn if a combination of panobinostat,
gemcitabine, busulfan, and melphalan and a stem cell transplant can help to control MM. The
safety of this combination will also be studied.
Busulfan Test Dose:
If you agree to take part in this study, you will receive a test dose of busulfan by vein
over about 60 minutes. This low-level test dose of busulfan will help the doctor decide what
dose of busulfan you will receive during the study. You will most likely receive this in an
outpatient clinic during the week before you are in the hospital. If it cannot be given to
you as an outpatient, you will be admitted to the hospital on Day -11 (11 days before your
stem cells are returned to your body) and the test dose will be given on Day -10. With stem
cell transplants, the days before you receive your stem cells are called minus days (Days
-11, -10, and so on). The day you receive the stem cells is called Day 0. The days after you
receive your stem cells are called plus days (Days +1, +2, and so on).
On the day of your busulfan test dose, blood (about 1 teaspoon each time) will be drawn for
pharmacokinetic (PK) testing of busulfan. PK testing measures the amount of study drug in
the body at different time points and will help the study doctor decide what your dose of
busulfan in this study should be. These blood samples will be drawn before your dose of
busulfan and then 10 more times over the next 11 hours.
The PK blood samples will be repeated again on the first day of high-dose busulfan treatment
(Day -8). A temporary heparin lock line will be placed in your vein to lower the number of
needle sticks needed for these draws. If it is not possible for the PK tests to be performed
for technical or scheduling reasons, you will receive the standard fixed dose of busulfan.
If you receive the busulfan test dose as an outpatient:
On Days -12, -11, and -10, you will receive palifermin by vein over about 30 seconds each
day to help decrease the risk of side effects in the mouth and throat.
You will be admitted to the hospital on Day -9.
If you receive the busulfan test dose as an inpatient:
On Days -14, -13, and -12 (the 3 days before you are admitted into the hospital), you will
receive palifermin by vein over about 30 seconds each day to help decrease the risk of side
effects in the mouth and throat.
You will be admitted to the hospital on Day -11.
Study Drug Administration:
Beginning on Day -9, you will swish the liquids caphosol and glutamine in your mouth 4 times
a day, for about 2 minutes each time. You will swish these liquids every day until you leave
the hospital. These drugs are used to help decrease the risk of side effects in the mouth
On Day -9 through Day -2, you will receive dexamethasone 2 times a day by vein over about 10
minutes, and you will take panobinostat by mouth 1 time a day.
On Day -8 you will receive gemcitabine by vein over about 4 hours.
On Days -8, -7, -6, and -5, you will receive busulfan by vein over about 3 hours a day.
On Day -3, you will receive gemcitabine by vein over about 4 hours and melphalan by vein
over 30 minutes.
On Day -2, you will receive melphalan by vein over about 30 minutes.
On Day -1, you will rest.
On Day 0, you will receive your stem cells by vein over about 30-60 minutes.
On Days 0, +1, and +2, you will receive 3 more doses of palifermin by vein over about 15-30
You will also be given standard drugs to help decrease the risk of side effects. You may ask
the study staff for information about how the drugs are given and their risks.
As part of standard care, you will remain in the hospital for about 3-4 weeks after the
transplant. After that, you will need to stay in the Houston area, so that you can continue
as an outpatient and be checked for infections and side effects.
Before you start study treatment, you will have a bone marrow biopsy and aspiration to check
the status of the disease. To collect a bone marrow biopsy and aspirate, an area of the hip
or other site is numbed with anesthetic, and a small amount of bone and bone marrow is
withdrawn through a large needle.
Length of Treatment:
The study treatment period is between Day -12 and Day +2, with follow-up described below.
You may be taken off study early if the disease gets worse, if intolerable side effects
occur, or if you are unable to follow study directions.
If for any reason you want to leave the study early, you must talk to the study doctor. It
may be life-threatening to leave the study after you have started to receive the study drugs
but before you receive the stem cell transplant. This is because your blood cell counts will
be dangerously low.
About 1 month, 100 days, 6 months, 1 year, and then about every 3-6 months for at least 2
years after the transplant for as long as the doctor thinks it is needed:
- You will have a physical exam.
- Blood (about 4 tablespoons) will be drawn for routine tests, to learn how the body has
accepted the transplanted cells, and to check the status of the disease.
About 100 days after the transplant, you will have a bone marrow biopsy and aspiration to
check the status of the disease. This will be repeated 1 time a year or earlier, if your
doctor thinks it is needed.
One (1) time a year, you will have x-rays of all the bones in your body to check the status
of the disease.
The study staff will also stay in contact with your local doctor to find out if the disease
comes back and to check how you are doing.
This is an investigational study. Panobinostat and melphalan are FDA approved for the
treatment of MM. Busulfan is FDA approved for the treatment of leukemia. Gemcitabine is FDA
approved for the treatment of lymphoma, breast cancer, and lung cancer. The use of these
study drugs in combination is investigational. The study doctor can explain how the study
drugs are designed to work.
Up to 80 participants will take part in this study. All will be enrolled at MD Anderson.
1. Age 18 to 65 years.
2. Refractory or relapsed myeloma, defined as one or more of the following: 2.1. Treated
with first-line therapy including at least 2 cycles of lenalidomide, bortezomib or
thalidomide, and one or more of the following: 2.1.1. Less than PR to first-line
therapy. 2.1.2. Relapse after 1st line therapy. 2.2. High-risk cytogenetics, defined
by del(13q) by conventional cytogenetics, or by del(17p), t(4;14), t(14;16), t(14;20)
or 1q+ by FISH. 2.3. Relapse after a prior ASCT. 2.4. Plasma cell leukemia. 2.5. Soft
3. Adequate renal function, as defined by serum creatinine </=1.8 mg/dL and/or estimated
serum creatinine clearance >/=50 ml/min.
4. Adequate hepatic function, as defined by SGOT and/or SGPT </=3 x upper limit of
normal; serum bilirubin and alkaline phosphatase </=2 x upper limit of normal, unless
proven to be due to disease involvement.
5. Adequate pulmonary function with FEV1, FVC and DLCO >/=50% of expected corrected for
hemoglobin and/or volume.
6. Adequate cardiac function with left ventricular ejection fraction >/=40%. No
uncontrolled arrhythmias or symptomatic cardiac disease.
7. Clinically euthyroid. Note: Patients are permitted to receive thyroid hormone
supplements to treat underlying hypothyroidism.
8. Zubrod performance status < 2.
9. Negative Beta-HCG test in a woman of child-bearing potential, defined as not
post-menopausal for 12 months or no previous surgical sterilization.
10. Availability of >/= 2.5 million CD34+ cells/kg previously apheresed.
11. Ability to provide written informed consent.
1. Prior whole brain irradiation.
2. Having received radiation therapy to head and neck (excluding eyes), and internal
organs of chest, abdomen or pelvis in the month prior to enrollment.
3. Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA >/=10,000
copies/mL, or >/= 2,000 IU/mL).
4. Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic
hepatitis C or positive hepatitis C serology.
5. Active infection requiring parenteral antibiotics.
6. Known positivity for human immunodeficiency virus (HIV).
7. Autologous stem-cell transplant in the previous six months.
8. Needing valproic acid for any medical condition during the study or within 5 days
prior to first panobinostat treatment.
9. Impairment of GI function or GI disease that may significantly alter the absorption
10. Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled
diabetes or active or uncontrolled infection) including abnormal laboratory values,
that could cause unacceptable safety risks or compromise compliance with the
11. Impaired cardiac function or clinically significant cardiac diseases, including any
one of the following: 11.1. History or presence of sustained ventricular
tachyarrhythmia. (Patients with a history of atrial arrhythmia are eligible but
should be discussed with Novartis prior to enrollment). 11.2 Any history of
ventricular fibrillation or torsade de pointes. 11.3. Bradycardia defined as HR< 50
bpm. Patients with pacemakers are eligible if HR >/= 50 bpm. 11.4. Screening ECG with
a QTc > 470 msec. 11.5. Right bundle branch block + left anterior hemiblock
(bifascicular block). 11.6. Myocardial infarction or unstable angina </= 12 months
prior to starting study drug. 11.7. Other clinically significant heart disease (e.g.,
CHF NY Heart Association class III or IV , uncontrolled hypertension, history of
labile hypertension, or history of poor compliance with an antihypertensive regimen).
12. Have undergone major surgery </= 4 weeks prior to starting study drug or who have not
recovered from side effects of such therapy.
13. Prior malignancy with in the last 5 years (except for basal or squamous cell
carcinoma, or in situ cancer of the cervix).
14. Any significant history of non-compliance to medical regimens or unwilling or unable
to comply with the instructions given to him/her by the study staff.
15. Received targeted agents within 2 weeks or within 5 half-lives of the agent and
active metabolites (whichever is longer) and who have not recovered from side effects
of those therapies.
16. Having received immunotherapy or chemotherapy within 2 weeks; or radiation therapy to
> 30% of marrow-bearing bone within </= 2 weeks prior to starting study treatment; or
who have not yet recovered from side effects of such therapies.
17. Grade >/= 3 nonhematological toxicity from prior therapy that has not resolved to </=